Q1 2022 13F Holders as of 3/31/2022
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
7.94M
-
Number of holders
-
51
-
Total 13F shares, excl. options
-
16.3M
-
Shares change
-
-1.23M
-
Total reported value, excl. options
-
$28.6M
-
Value change
-
-$2.24M
-
Put/Call ratio
-
5.95
-
Number of buys
-
19
-
Number of sells
-
-20
-
Price
-
$1.75
Significant Holders of X4 Pharmaceuticals, Inc - Common Stock, par value $0.001 per share (XFOR) as of Q1 2022
63 filings reported holding XFOR - X4 Pharmaceuticals, Inc - Common Stock, par value $0.001 per share as of Q1 2022.
X4 Pharmaceuticals, Inc - Common Stock, par value $0.001 per share (XFOR) has 51 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 16.3M shares
.
Largest 10 shareholders include Bain Capital Life Sciences Investors, LLC (3.02M shares), Tri Locum Partners LP (1.72M shares), Point72 Asset Management, L.P. (1.63M shares), ORBIMED ADVISORS LLC (1.37M shares), Ikarian Capital, LLC (1.37M shares), AXA S.A. (1.15M shares), AIGH Capital Management LLC (998K shares), BVF INC/IL (848K shares), VANGUARD GROUP INC (653K shares), and MILLENNIUM MANAGEMENT LLC (404K shares).
This table shows the top 51 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.